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Conjugates of Cryptophycin and RGD or isoDGR
Peptidomimetics for Targeted Drug Delivery
Adina Borbély,[a] Eduard Figueras,[a] Ana Martins,[a, b] Lizeth Bodero,[c]
André Raposo Moreira Dias,[d] Paula López Rivas,[d] Arianna Pina,[d] Daniela Arosio,[e]
Paola Gallinari,[b] Marcel Frese,[a] Christian Steinkühler,[b] Cesare Gennari,[d] Umberto Piarulli,[c]
and Norbert Sewald*[a]
RGD-cryptophycin and isoDGR-cryptophycin conjugates were
synthetized by combining peptidomimetic integrin ligands and
cryptophycin, a highly potent tubulin-binding antimitotic agent
across lysosomally cleavable Val-Ala or uncleavable linkers. The
conjugates were able to effectively inhibit binding of biotiny-
lated vitronectin to integrin αvβ3, showing a binding affinity in
the same range as that of the free ligands. The antiproliferative
activity of the novel conjugates was evaluated on human
melanoma cells M21 and M21-L with different expression levels
of integrin αvβ3, showing nanomolar potency of all four
compounds against both cell lines. Conjugates containing
uncleavable linker show reduced activity compared to the
corresponding cleavable conjugates, indicating efficient intra-
cellular drug release in the case of cryptophycin-based SMDCs.
However, no significant correlation between the in vitro bio-
logical activity of the conjugates and the integrin αvβ3
expression level was observed, which is presumably due to a
non-integrin-mediated uptake. This reveals the complexity of
effective and selective αvβ3 integrin-mediated drug delivery.
1. Introduction
Chemotherapeutic agents used in traditional tumor therapy do
not preferentially accumulate at the tumor site and are often
associated with poor pharmacokinetics leading to inferior
efficacy and severe side effects due to systemic toxicity. An
emerging approach to minimize chemotherapy side effects and
maximize tumor specificity, is the covalent conjugation of
cytotoxic drugs to antibodies that provide site-specific targeted
delivery of the toxin.[1–3] The resulting antibody-drug conjugates
(ADCs) have a definitive impact on anticancer drug develop-
ment with currently four ADCs on the market (Adcetris®,
Kadcyla®, Mylotarg®, and Besponsa®) and approximately 70
candidates in clinical trials.[4] Although ADCs show great clinical
benefit and success on the market, further development is
required to address limitations like high manufacturing costs,
inefficient tissue penetration and immunogenicity, in particular
for the treatment of solid tumors.[5] As an alternative, small-
molecule-drug conjugates (SMDCs) have the potential to over-
come drawbacks of ADCs. In this case, the cytotoxic agent is
connected to a small synthetic ligand that selectively binds to
an appropriate target overexpressed on the tumor cell
surface.[6,7]
Integrins, a family of 24 transmembrane heterodimers
composed of 18α and 8β integrin subunits, are considerable
targets in anticancer therapy due to their involvement in many
steps of cancer progression.[8] The cell adhesion protein, integrin
αvβ3 is highly expressed on endothelial and tumor cells of
various solid tumors such as glioma, gastric cancer, non-small
cell lung cancer, prostate, and pancreatic cancer.[9–11] In
addition, integrin αvβ3 plays a vital role in cancer progression,
angiogenesis, and metastasis. Therefore, it has been widely
considered as potential target antigen.[8,12,13] Integrin αvβ3 binds
endogenous ligands, like vitronectin, by recognizing the
tripeptide sequence Arg  Gly  Asp (RGD) as the minimal binding
motif.[14] As a result, various RGD-containing synthetic peptides
and peptidomimetics have been developed and some of them
demonstrate high binding affinity to different integrins.[15–17]
Several ligands with strong binding affinity and integrin
subtype selectivity have been successfully conjugated to differ-
ent cytotoxic agents, and have been investigated for tumor
targeting applications.[18,19]
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Besides the RGD sequence, the isoaspartyl-containing
sequence isoAsp  Gly  Arg (isoDGR) was identified as an integrin
ligand. Hence, there has been increasing interest in employing
isoDGR peptides as RGD analogues for integrin targeting.[20,21]
There is a growing body of evidence suggesting that this class
of ligands are true integrin αvβ3 antagonists, unlike the RGD
peptides, which induce integrin conformational changes upon
binding, as well as receptor activation.[22,23] Based on these
findings, a panel of cyclic RGD and isoDGR peptidomimetic
integrin ligands containing a diketopiperazine (DKP) scaffold
have been developed. Importantly, the cyclo[DKP-RGD] 1 and
cyclo[DKP-isoDGR] 3 (Figure 1) are selective integrin αvβ3 ligands
with low nanomolar affinity.[24,25] Functionalized analogues 2
and 4 have been conjugated to different anticancer drugs, such
as paclitaxel,[26–31] camptothecin[32] and α-amanitin[33] across
different linkage systems including ester, ether, carbonate or
carbamate bond, involving non-cleavable, disulfide, elastase
cleavable NPV, and lysosomally cleavable Val  Ala, Phe  Lys or
GFLG linkers.
Although the ligand plays a key role for efficient targeting,
the high potency of the cytotoxic drug is also a crucial criterion
for optimal SMDC design.[2] Cryptophycins are compelling
antimitotic payloads for tumor targeting applications, owing to
their high activity as tubulin polymerization inhibitors, relative
hydrophilicity and ability to overcome multidrug resistance.[34]
Initially the synthetic analogue cryptophycin-52 (5, Figure 1)
was developed and clinically investigated as an antitumor agent
on its own. However, neurotoxic side effects and the lack of
activity led to the failure of this drug candidate in clinical phase
II.[35,36] Further research has been focused on the investigation of
structural moieties that are essential for the biological activity.
Consequently, a large variety of synthetic analogues have been
designed and tested for structure-activity relationship (SAR)
studies.[37–39] More recently, cryptophycin derivatives bearing a
functional handle suitable for attachment to tumor targeting
peptides or antibodies have come to the forefront.[34,40–43] In this
context, the unit A-modified chlorohydrin derivative (6, Fig-
ure 1) and the glycinate of the chlorohydrin hydroxyl group (7,
Figure 1) are highly potent in vitro and in vivo.[44] The latter has
been successfully conjugated to trastuzumab targeting HER2,[45]
acetazolamide targeting CAIX,[46] and other RGD-based integrin
ligands.[47]
2. Results and Discussion
Here we focus on the conjugation of the cryptophycin-55
glycinate derivative to the functionalized cyclo[DKP-RGD] and
cyclo[DKP-isoDGR] peptidomimetics for integrin targeted deliv-
ery. The conjugates were designed to connect the integrin
ligands to the cytotoxin across the lysosomally cleavable
Val  Ala linker (10 and 11, Scheme 1). The cathepsin B sensitive
peptide linker combined with the p-aminobenzylcarbamate
(PABC) self-immolative spacer is widely used to ensure efficient
release of the free drug upon endocytosis.[48] Conjugates with
uncleavable linker were also prepared (13 and 14, Scheme 1).
Presumably the latter are not substrates of enzymatic cleavage;
therefore, the drug should be released only after hydrolysis of
ligand-linker components resulting in decreased in vitro anti-
tumor activity of the conjugate compared to the unconjugated
Figure 1. Chemical structure of ligands: cyclo[DKP-RGD] (1), NH2CH2  cyclo[DKP-RGD] (2), cyclo[DKP-isoDGR] (3), NH2CH2  cyclo[DKP-isoDGR] (4) and cytotoxic
drugs: cryptophycin-52 (5), cryptophycin-55 (6) and cryptophycin-55 glycinate (7).
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drug and the conjugates with cleavable linker. To improve the
water solubility of the conjugate and ensure flexibility of the
construct, a PEG4 spacer was inserted between the ligand and
the triazole ring, used as connection point with the linker.
We evaluated the four conjugates for their ability to inhibit
binding of biotinylated vitronectin to isolated integrin αvβ3 in
comparison with the free ligands. We tested the in vitro
cytotoxic activity of the conjugates against the human
melanoma cells M21 and M21-L with different integrin
expression levels.
2.1. Synthesis
The RGD and isoDGR peptidomimetic-cryptophycin conjugates
10, 11, 13, and 14 were synthetized as shown in Scheme 1.
The linker Fmoc  Val  Ala  PAB[27] was deprotected by piper-
idine and the crude free amine was subsequently reacted with
4-pentynoic acid. Then, the hydroxyl group was activated using
bis(4-nitrophenyl) carbonate (Scheme S1 in the Supporting
Information). The resulting alkyne-functionalized activated link-
er 8 was conjugated to cryptophycin-55 glycinate[46] by forming
a carbamate to give compound 9. The PEG4-containing azido-
functionalized cyclo[DKP-RGD] and cyclo[DKP-isoDGR] ligands
were prepared as previously reported.[29,33] Final conjugation
was achieved by copper(I)-catalyzed azide  alkyne cycloaddition
(CuAAC “click” reaction) between compound 9 and cyclo[DKP-
RGD]-PEG4-azide or cyclo[DKP-isoDGR]-PEG4-azide, respectively.
For the synthesis of uncleavable conjugates 4-pentynoic
acid was coupled to cryptophycin-55 glycinate (7) via amide
bond to afford compound 12. This was subjected to CuAAC
reaction with the respective ligands to give the final conjugates
13 and 14. Compounds 8–14 were characterized by NMR,
HPLC-MS and HRMS (see Supporting Information).
2.2. Competitive Integrin Binding Assays
Conjugates were evaluated in vitro for their binding affinity to
human αvβ3 integrin in comparison with the free RGD and
isoDGR ligands. Competitive binding assays were performed by
incubation of immobilized αvβ3 integrin with increasing concen-
trations of test compounds (10  5–10  12 M) in the presence of
the ECM protein, vitronectin (1 μgmL  1). The concentrations
causing 50% inhibition of biotinylated vitronectin (IC50) are
listed in Table 1. As it is shown, free ligands as well as
conjugates efficiently inhibit the biotinylated vitronectin bind-
ing to αvβ3 integrin with IC50 values in the low nanomolar range.
Comparing the binding affinity of the conjugates and ligands
we can conclude that conjugates retained high binding affinity.
The linker type has only a minimal effect, conjugates with
uncleavable linker displayed a slightly reduced affinity, presum-
ably because of the shorter linker between the ligand and the
drug. Similar results were reported for analogous conjugates of
the cyclo[DKP-RGD] and cyclo[DKP-isoDGR] ligands and paclitax-
el or α-amanitin.[29,33] In addition, high selectivity for αvβ3
integrin was reported for cyclo[DKP-RGD]-paclitaxel conjugates
involving various lysosomally cleavable Val  Ala or GFLG
linkers.[31] This indicates that conjugation of a drug to the
respective ligands does not compromise specificity and we
expect that the selectivity of the RGD- and isoDGR-cryptophycin
conjugates towards αvβ3 integrin subtype is maintained.
2.3. Cell Viability Assays
The cytotoxicity of the unconjugated drug (7) and cryptophy-
cin-conjugates (10, 11, 13, 14) was assessed for two cell lines
Scheme 1. Synthesis of cyclo[DKP-RGD]-PEG4-Val  Ala-PABC-Cry-55gly (10), cyclo[DKP-isoDGR]-PEG4-Val  Ala-PABC-Cry-55gly (11), cyclo[DKP-RGD]-PEG4-uncl-
Cry-55gly (13), and cyclo[DKP-isoDGR]-PEG4-uncl-Cry-55gly (14). Reagents and conditions: a) 7, DIPEA, DMF, RT, 4 h; b) cyclo[DKP-RGD]-PEG4-N3, CuSO4 ·5H2O,
sodium ascorbate, 1 : 1 DMF/H2O, 35 °C, 24 h; c) cyclo[DKP-isoDGR]-PEG4-N3, CuSO4 ·5H2O, sodium ascorbate, 1 : 1 DMF/H2O, 35 °C, 24 h; d) 7, PyBOP, HOBt,
DIPEA, DMF, RT, 4 h.
Table 1. Inhibition of biotinylated vitronectin binding to human integrin
αvβ3. IC50 values were determined as the compound concentration
necessary for 50% inhibition of biotinylated vitronectin binding as
calculated using the software GraphPad Prism. All values are the
average� standard deviation of duplicate measurements.
Cmpd Structure IC50 [nM] αvβ3
1 cyclo[DKP-RGD] 4.5�1.1
3 cyclo[DKP-isoDGR] 9.2�1.1
10 cyclo[DKP-RGD]-VA-Cry-55gly 7.2�1.5
11 cyclo[DKP-isoDGR]-VA-Cry-55gly 5.5�2.8
13 cyclo[DKP-RGD]-Cry-55gly 24.1�1.0
14 cyclo[DKP-isoDGR]-Cry-55gly 10.2�0.4
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with different expression levels of the integrin. The M21 human
melanoma (αvβ3 positive) and M21-L (αvβ3 negative) model was
used to characterize in vitro the tumor-targeting ability of the
novel conjugates.[49] The presence of the integrin subunit αv
and the integrin heterodimer αvβ3 on the cell membrane was
confirmed by flow cytometry analysis (Figure S1 in the Support-
ing Information). The cells were treated with increasing
concentrations of the free drug and conjugates 10, 11, 13, 14,
respectively, for 2 hours, then the medium was replaced with
fresh medium and the incubation was continued for additional
70 hours. The short treatment time aimed to minimalize altered
antiproliferative activity caused by incidental extracellular linker
cleavage and undesired drug release, as well as intended to
resemble more closely the in vivo experimental conditions. The
cell viability was measured in an MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay (Figure 2, Table 2).
The cryptophycin conjugates display high in vitro potency
with IC50 values between 22.3–287.5 nM, showing slightly
reduced activity compared to cryptophycin-55 glycinate. More-
over, conjugates bearing cleavable linker (10, 11) are more
cytotoxic than the corresponding uncleavable conjugates (13,
14). This underlines that higher potency of the conjugates may
be associated with the intracellular cathepsin-mediated drug
release, while lower cytotoxicity correlates with less specific
linker degradation. Although the intracellular enzymatic cleav-
age of peptide-linked ADCs and SMDCs is a well-known
process,[50] this study is the first head-to-head comparison for
cryptophycin-based SMDCs.
All four conjugates were found to exhibit similar cytotoxic
activity on the antigen-positive and antigen-negative cell line,
indicating that there is no substantial correlation between the
expression level of integrin and the observed biological activity.
In this regard, it has to be noted that the αvβ3-negative M21-L
cell line seems to be more sensitive to cryptophycin and
cryptophycin conjugates. It was previously reported that the
cytotoxicity of cyclo[DKP-isoDGR]-α-amanitin conjugates was
not integrin-specific when tested on human glioblastoma U-87
(αvβ3+), breast adenocarcinoma MDA-MB-468 (αvβ3  ), and it
was hypothesized that the internalization process was mediated
by integrins different from αvβ3 (e.g. αvβ5).
[33] This observation
prompted us to select the isogenic M21 and M21-L cell lines for
the in vitro evaluation of cryptophycin conjugates. The M21-L
cell line was considered a valid negative control, as these cells
completely lack the integrin αv subunit. The deficient expression
of the αv at the mRNA level leads to the absence of not only of
integrin αvβ3, but also the other αv integrin heterodimers (e.g.
αvβ5, αvβ6).
[51] Nevertheless, it is known that the RGD-motif is
not exclusively recognized by the αv-integrin subfamily but also
by other integrins, namely the αIIbβ3, α5β1, and α8β1.
[52] For this
reason, targeting one distinct integrin subtype using small RGD
ligand-based SMDCs is considered to be challenging. Flow
cytometry analysis shows similar expression level of integrin
α5β1 in the M21 and M21-L cells, that is comparable with the
αvβ3 integrin expression level in the antigen positive cell
line.[53–55] Although cyclic RGD and isoDGR peptidomimetic
ligands have been shown to bind to α5β1 100-fold less effective
than to αvβ3 (1: α5β1 IC50=532 nM,[56] 3: α5β1 IC50=1066 nM,
determined according to ref. 56) the presence of this receptor
might play a role in the recognition and internalization of RGD-
and isoDGR-cryptophycin conjugates, resulting in similar activity
against both cell lines.
On the other hand, it has been shown that the cyclo-RGDfK-
carboxyfluorescein peptide targeting αvβ3 integrin was taken up
by antigen-positive and antigen-negative cells to a similar
extent, suggesting that the endocytosis of cyclo-RGD peptides
is integrin-independent, and proceeds by a fluid-phase
pathway.[57] Furthermore, it has been reported that increased
Table 2. Cytotoxic potencies of free cryptophycin-55 glycinate and
cryptophycin-conjugates against M21 and M21-L cell lines upon 2 h
treatment and 70 h additional incubation.
Structure IC50 [nM]
M21
(αvβ3+)
IC50 [nM]
M21-L
(αv  , αvβ3  )
Cry-55gly (7) 0.75�0.11 0.14�0.08
cyclo[DKP-RGD]-VA-Cry-55gly (10) 72.7�11.2 22.3�2.0
cyclo[DKP-isoDGR]-VA-Cry-55gly (11) 122.6�18.6 32.6�3.0
cyclo[DKP-RGD]-Cry-55gly (13) 261.3�45.8 203.0�27.7
cyclo[DKP-isoDGR]-Cry-55gly (14) 287.5�35.9 140.8�13.3
Figure 2. Cell viability determined in an MTT assay with M21 (left), M21-L (right) cells after treatment with Cry-55gly (7), cyclo[DKP-RGD]-cryptophycin and
cyclo[DKP-isoDGR]-cryptophycin conjugates. Curves were obtained by non-linear regression, error bars represent the standard deviation of triplicate
measurements, the measurements were repeated twice.
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hydrophobicity of conjugates caused by the hydrophobic
character of the cytotoxic drug may facilitate unwanted non-
specific interactions with the cell surface and can result in
passive conjugate uptake into the antigen-negative cell.[58]
Indeed, cryptophycins are highly hydrophobic and the cellular
uptake of 3H-cryptophycin-52 by THP-1 and H-125 cells was
reported to be fast and irreversible.[59] The nonspecific intra-
cellular uptake of the RGD- and isoDGR-cryptophycin conju-
gates, promoted by the hydrophobic drug or the overall
hydrophobicity of the conjugates, may be an additional factor
implicated in the observed in vitro potencies. Further increasing
the linker hydrophilicity may reduce these undesired interac-
tions and can result in enhanced selectivity.
3. Conclusions
In summary, we have investigated the synthesis and biological
activity of novel cyclo[DKP-RGD]-cryptophycin and cyclo[DKP-
isoDGR]-cryptophycin conjugates aiming at integrin-mediated
drug delivery. The cytotoxic payload is connected to the
respective peptidomimetic ligand via the protease cleavable
Val  Ala linker in combination with PABC self-immolative moiety
or a non-cleavable spacer. All four conjugates retain high
binding affinity towards isolated αvβ3 integrin, similarly to the
free ligands. In vitro, the cryptophycin-conjugates were found
to be highly potent against both human melanoma cells M21
and M21-L with IC50 values in the nanomolar range. Conjugates
containing uncleavable linker demonstrated moderately de-
creased activity in comparison with analogous cleavable
conjugates. Although RGD- and isoDGR-ligands show high
specificity for αvβ3 integrin, no correlation could be found
between the in vitro antitumor activity of the conjugates and
the αvβ3 integrin expression level, revealing the complexity of
effective and selective αvβ3 integrin-mediated drug delivery. We
assume that our SMDCs may internalize by an αv-integrin
independent pathway: endocytosis could either be mediated by
integrin α5β1, or by nonspecific, fluid-phase uptake, in which
the high overall hydrophobicity of the conjugates could also
play a role. Nonetheless, the high activity of cryptophycin
conjugates encourages us to further investigate and improve
the selectivity in tumor-targeted drug delivery.
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